Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,963 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,963 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Open enrollment, early-phase tilt
Prostate Cancer has 749 registered US clinical trials, 275 of them open to new participants right now, about 37% of the total.
- 275
- recruiting participants now
- 37%
- of trials open to enrollment
- 75
- in Phase 3-4 (later-stage)
- 53
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #4 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 4 of 15
Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
University of Chicago
NCT04705038
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
Northwell Health
NCT05384535
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Cellvax Therapeutics
NCT06636682
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
NCT04354064
The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
Vivek Narayan
NCT06064149
Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI
University of California, San Diego
NCT04992728
Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance
M.D. Anderson Cancer Center
NCT05840484
ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
Indiana University
NCT05879913
The Florida ASCENT Study
University of Florida
NCT07042243
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
University of Colorado, Denver
NCT05515978
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
Hackensack Meridian Health
NCT04263025
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics
NCT06399757
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT06347705
Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy
NYU Langone Health
NCT06542757
64Cu-GRIP B in Patients With Advanced Malignancies
Rahul Aggarwal
NCT05888532
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06138067
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics
NCT06778863
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
University of Chicago
NCT05726292
Understanding of Genetics by Men at Risk for Prostate Cancer
Mayo Clinic
NCT04550845
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
University of Maryland, Baltimore
NCT06212583
Jump: MR Simulation For Radiation Therapy Master Protocol
Brigham and Women's Hospital
NCT04545957
Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors
Barbara Ann Karmanos Cancer Institute
NCT07436078
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Palette Life Sciences
NCT06496256
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics
NCT05413850
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
Ivan de Kouchkovsky, MD
NCT02526368
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex
NCT06440005
SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06389097
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
University of California, San Francisco
NCT06171139
Two Fraction Prostate SBRT With DIL SIB
NYU Langone Health
NCT05864196
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
Dana-Farber Cancer Institute
NCT06040125
Feasibility of Timesaving When Using Histolog Confocal Laser Endomicroscopy for Margin Assessment in Prostatectomy Specimen
Icahn School of Medicine at Mount Sinai
NCT07141121
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
Ivan de Kouchkovsky, MD
NCT04346225
Stratagen Quantitative Prostate MRI Platform Pilot Study
Stratagen Bio
NCT06985238
Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
University of Utah
NCT07032584
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
Hackensack Meridian Health
NCT07011342
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
Proton Collaborative Group
NCT00969111
4-aminopyridine Treatment for Nerve Injury
John Elfar
NCT03701581
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
University of Texas Southwestern Medical Center
NCT07313241
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
David Oh
NCT03821246
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
Debiopharm International
NCT06395753
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Cancer Institute (NCI)
NCT06096870
Pembro With Radiation With or Without Olaparib
Zin W Myint
NCT05568550
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
Dana-Farber Cancer Institute
NCT05327465
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
VA Office of Research and Development
NCT06084338
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
University of California, San Francisco
NCT03933670
Castrate Resistant Prostate Cancer Enhertu Therapy
Washington D.C. Veterans Affairs Medical Center
NCT06610825
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
University of Chicago
NCT06171269
GU-01: Glycyrrhizin in Prostate Cancer
University of Illinois at Chicago
NCT06378346
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
H. Lee Moffitt Cancer Center and Research Institute
NCT03495427
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
University of Wisconsin, Madison
NCT04989946
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Prostate Cancer right now
275 recruiting of 749 indexed (37% open).
Phase mix: 75 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (53 trials), 9 others listed. 50 shown below, recruiting first. #4 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Prostate Cancer?
PlainTrial tracks 749 US clinical trials for Prostate Cancer, of which 275 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Prostate Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.